Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
复制标题
作者：
我们开发了一种新的标记小鼠细胞系来研究卵巢癌。STOSE小鼠细胞系表达荧光素酶标签，通过成像实现实时肿瘤监测。我们描述了小鼠细胞系的生长特征，并在形成的肿瘤中鉴定了免疫细胞。我们用免疫疗法治疗小鼠，对肿瘤生长没有影响。总的来说，STOSE。M1 luc模型与人类卵巢癌非常相似，将进一步帮助我们理解和治疗这种疾病。尽管手术和靶向治疗取得了进展，但患有高级别浆液性卵巢癌的妇女的预后仍然很差。此外，与其他癌症不同，免疫疗法对卵巢癌患者的预后影响最小。由于缺乏相关的同基因卵巢癌模型来研究肿瘤免疫和评估免疫疗法，这方面的进展受到阻碍。为了解决这个问题，我们开发了一种荧光素酶标记的小鼠高级别浆液性卵巢癌模型，STOSE。M1卢克。我们定义了它的生长特征、免疫细胞库和对抗PD-L1免疫治疗的反应。与人类卵巢癌一样，我们证明该模型对免疫检查点调节剂不太敏感。通过开发STOSE。M1 - luc模型，将有可能探索免疫疗法耐药的机制，并评估治疗卵巢癌的新治疗方法。
We developed a new labeled mouse cell line to study ovarian cancer. The STOSE mouse cell line was engineered to express a luciferase label to enable real-time tumor monitoring by imaging. We characterized the growth of the cell line in mice and identified the immune cells within the formed tumors. We treated the mice with immunotherapy, which had no effect on tumor growth. Overall, the STOSE.M1 luc model closely resembles ovarian cancer in humans and will further aid in our understanding and treatment of this disease. Despite advances in surgery and targeted therapies, the prognosis for women with high-grade serous ovarian cancer remains poor. Moreover, unlike other cancers, immunotherapy has minimally impacted outcomes in patients with ovarian cancer. Progress in this regard has been hindered by the lack of relevant syngeneic ovarian cancer models to study tumor immunity and evaluate immunotherapies. To address this problem, we developed a luciferase labeled murine model of high-grade serous ovarian cancer, STOSE.M1 luc. We defined its growth characteristics, immune cell repertoire, and response to anti PD-L1 immunotherapy. As with human ovarian cancer, we demonstrated that this model is poorly sensitive to immune checkpoint modulators. By developing the STOSE.M1 luc model, it will be possible to probe the mechanisms underlying resistance to immunotherapies and evaluate new therapeutic approaches to treat ovarian cancer.
登录
查看更多内容
影响因子：
3.7
作者：
Huang L;Bommireddy R;Munoz LE;Guin RN;Wei C;Ruggieri A;Menon AP;Li X;Shanmugam M;Owonikoko TK;Ramalingam SS;Selvaraj P
通讯作者：
Selvaraj P
影响因子：
5.2
作者：
Doetzer, Katharina;Schlueter, Friederike;Mayer, Barbara
通讯作者：
Mayer, Barbara
DOI：
10.1186/s13046-020-01775-9
发表时间：
2020-11-30
期刊：
Journal of experimental & clinical cancer research : CR
影响因子：
--
作者：
De Donato M;Babini G;Mozzetti S;Buttarelli M;Ciucci A;Arduini G;De Rosa MC;Scambia G;Gallo D
通讯作者：
Gallo D
影响因子：
3.1
作者：
Henriksen, Jon Roikjaer;Donskov, Frede;Steffensen, Karina Dahl
通讯作者：
Steffensen, Karina Dahl
DOI：
10.1073/pnas.1003345107
发表时间：
2010-04-27
影响因子：
11.1
作者：
Matsuzaki, Junko;Gnjatic, Sacha;Odunsi, Kunle
通讯作者：
Odunsi, Kunle